Lb Pharmaceuticals (LBRX) Cash from Investing Activities (2024 - 2026)

Lb Pharmaceuticals' Cash from Investing Activities history runs 3 years deep, the most recent figure standing at -$32000.0 for Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 100.64% year-over-year to -$32000.0; the TTM figure through Mar 2026 stood at $18.4 million (changed N/A YoY), while the FY2025 annual figure was -$39.9 million, down 271.68% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$32000.0, up from -$40000.0 in the prior quarter.
• The five-year high for Cash from Investing Activities was $13.5 million in Q4 2024, with the low at -$40000.0 in Q4 2025.
• The 3-year median for Cash from Investing Activities is $2.5 million (2025), against an average of $4.6 million.
• The sharpest annual moves came in 2025 and 2026: Cash from Investing Activities tumbled 100.3% in 2025, then sank 100.64% in 2026.
• Lb Pharmaceuticals' Cash from Investing Activities stood at $13.5 million in 2024, then tumbled by 100.3% to -$40000.0 in 2025, then rose by 20.0% to -$32000.0 in 2026.
• Business Quant data shows LBRX's Cash from Investing Activities at -$32000.0 in Q1 2026, -$40000.0 in Q4 2025, and $5.0 million in Q1 2025.